Assessment of Intestinal Absorption of Vitexin-2″-O-Rhamnoside in Hawthorn Leaves Flavonoids in Rat Using In Situ and In Vitro Absorption Models

REFERENCES

• Amidon G. L., Lennernäs H., Shah V. P., Crison A. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995; 12: 413–420
   PubMed Web of Science ®Google Scholar
• Ammon H. P. T., Händel M. Crataegus, toxicology and pharmacology: I. Toxicity. Planta Med. 1981a; 43: 105–120
   PubMed Web of Science ®Google Scholar
• Ammon H. P. T., Händel M. Crataegus, toxicology and pharmacology: II. Pharmacodynamics. Planta Med. 1981b; 43: 209–239
   PubMed Web of Science ®Google Scholar
• Artursson P., Ungell A. L., Löfroth J. E. Selective paracellular permeability in two models of intestinal absorption: Cultured monolayers of human intestinal epithelial cells and rat intestinal segments. Pharm. Res. 1993; 10: 1123–1129
   PubMed Web of Science ®Google Scholar
• Barthe L., Bessouet M., Woodley J. F., Houin G. The improved everted gut sac: A simple method to study intestinal P-glycoprotein. Int. J. Pharm. 1998; 173: 255–258
   Web of Science ®Google Scholar
• Barthe L., Woodley J., Houin G. Gastrointestinal absorption of drugs: Methods and studies. Fundam. Clin. Pharmacol. 1999; 13: 154–168
   PubMed Web of Science ®Google Scholar
• Benet L. Z., Wu C.-Y., Hebert M. F., Wacher V. J. Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. J. Control Release 1996; 39: 139–143
   Web of Science ®Google Scholar
• Berggren S., Hoogstraate J., Fagerholm U., Lennernäs H. Characterization of jejunal absorption and apical efflux of orpivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models. Eur. J. Pharm. Sci. 2004; 21: 553–560
   PubMed Web of Science ®Google Scholar
• Christian J. F. H., Wilson S. C., Thomas M. Survival and prognosis: Investigation of Crataegus extract WS 1442 in congestive heart failure SPICE rationale—Study design and study protocol. Eur. J. Heart. Fail. 2000; 2: 431–437
   PubMed Web of Science ®Google Scholar
• Cummins C. L., Salphati L., Reid M. J. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: Studies using the rat single-pass intestinal perfusion model. J. Pharmacol. Exp. Ther. 2003; 305: 306–314
   PubMed Web of Science ®Google Scholar
• Ding X. B., Jiang Y. Q., Zhong Y., Zuo C. X. Study on chemical constituents in hawthorn leaves. China J. Chin. Materia Medica. 1990; 15: 295–297
   Google Scholar
• Fagerholm U., Johansson M., Lennernäs H. Comparison between permeability coefficients in rat and human jejunum. Pharm. Res. 1996; 13: 1336–1342
   PubMed Web of Science ®Google Scholar
• Gan L.-S. L., Moseley M. A., Khosla B., Augustijns P. F., Bradshaw T. P., Hendren R.W., et al. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: Interaction between the two biochemical barriers to intestinal transport. Drug Metab. Dispos. 1996; 24: 344–349
   PubMed Web of Science ®Google Scholar
• Grassi M., Cadelli G. Theoretical considerations on the in vivo intestinal permeability determination by means of the single pass and recirculation techniques. Int. J. Pharm. 2001; 229: 95–105
   PubMed Web of Science ®Google Scholar
• Guo J., Ping Q., Dong J., Qi S., Feng L., Li Z., et al. Transport of leuprolide across rat intestine, rabbit intestine and Caco-2 cell monolayer. Inter. J. Pharm. 2004; 278: 415–422
   PubMed Web of Science ®Google Scholar
• Hebert M. F. Contribution of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv. Drug Deliv. Rev. 1997; 27: 201–214
   PubMed Web of Science ®Google Scholar
• Kruijtzer C. M. F., Beijnen J. H., Rosing H., ten Bokkel Huinink W. W., Schot M., Jewell R.C., et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J. Clin. Oncol. 2002; 20: 2943–2950
   PubMed Web of Science ®Google Scholar
• Lennernäs H., Nylander S., Ungell A. L. Jejunal permeability: A comparison between the Ussing chamber technique and the single-pass perfusion in humans. Pharm. Res. 1997; 14: 667–671
   PubMed Web of Science ®Google Scholar
• Lennernäs H., Palm K., Fagerholm U., Artursson P. Comparison between active and passive drug transport in human intestinal epithelium (Caco-2) cells in vitro and human jejunum in vivo. Int. J. Pharm. 1996; 127: 103–107
   Web of Science ®Google Scholar
• Lindahl A., Sandström R., Ungell A. L., Lennernäs H. Concentration- and region-dependent intestinal permeability of fluvastatin in the rat. J. Pharm. Pharmacol. 1998; 50: 737–744
   PubMed Web of Science ®Google Scholar
• Lown K. S., Mayo R. R., Leichtman A. B., Hsiao H.-L., Turgeon D. K., Schmiedlin-Ren P., et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporin. Clin. Pharmacol. Ther. 1997; 62: 248–260
   PubMed Web of Science ®Google Scholar
• Salphati L., Childers K., Pan L., Tsutsui K., Takahashi L. Evaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in man. J. Pharm. Pharmacol. 2001; 53: 1007–1013
   PubMed Web of Science ®Google Scholar
• Sha X. Y., Fang X. L. Transport characteristics of 9-nitrocamptothecin in the human intestinal cell line Caco-2 and everted gut sacs. Inter. J. Pharm. 2004; 272: 161–171
   PubMed Web of Science ®Google Scholar
• Singhal D., Ho N. F., Anderson B. D. Absorption and intestinal metabolism of purine dideoxynucleosides and an adenosine deaminase-activated prodrug of 2’,3’-dideoxyinosine in the mesenteric vein cannulated rat ileum. J. Pharm. Sci. 1998; 87: 569–577
   PubMed Web of Science ®Google Scholar
• Stewart B. H., Chan O. H., Jezyk N., Fleisher D. Discrimination between drug candidates using models for evaluation of intestinal absorption. Adv. Drug Deliv. Rev. 1997; 23: 27–45
   Web of Science ®Google Scholar
• Tauchert M. Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. Am. Heart J. 2002; 143(5)910–915
   PubMed Web of Science ®Google Scholar
• Terao T., Hisanaga E., Sai Y., Tamai I., Tsuji A. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J. Pharm. Pharmacol. 1996; 48: 1083–1089
   PubMed Web of Science ®Google Scholar
• Thiebault F., Tsuruo T., Hamada H., Gottesman M. M., Pastan I. Cellular localisation of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U.S.A. 1987; 84: 7735–7738
   PubMed Web of Science ®Google Scholar
• Troutman M. D., Thakker D. R. Novel experimental parameters to quantify the modulation of absorption and secretary transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm. Res. 2003; 20: 1200–1209
   PubMed Web of Science ®Google Scholar
• Varma M. V. S., Ashokra Y. J, Dey C. S., Panchagnula R. P-glycoprotein inhibitors and their screening: A perspective from bioavailability enhancement. Pharmacol. Res. 2003; 48: 347–356
   PubMed Web of Science ®Google Scholar
• Varma M. V. S., Kapoor N., Sarkar M., Panchagnula R. Simultaneous determination of digoxin and permeability markers in rat in situ intestinal perfusion samples by RP-HPLC. J. Chromatogr. B. 2004; 813: 347–352
   PubMed Web of Science ®Google Scholar
• Varma M. V. S., Khandavilli S., Ashokraj Y., Jain A., Dhanikula A., Sood A., et al. Biopharmaceutic classification system: A scientific framework for pharmacokinetic optimization in drug research. Curr. Drug Metab. 2004; 5: 375–388
   PubMed Web of Science ®Google Scholar
• Varma M. V. S., Sarkar M., Kapoor N., Panchagnula R. pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs 1: Simultaneous determination of quinidine and permeability markers in rat in situ perfusion samples. J. Chromatogr. B. 2005; 816: 243–249
   PubMed Web of Science ®Google Scholar
• Watkins P. B. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev. 1997; 27: 161–170
   PubMed Web of Science ®Google Scholar
• Ying X. X., Lu X. M., Sun X. H., Li X. Q., Li F. M. Determination of vitexin-2-O-rhamnoside in rat plasma by ultra-performance liquid chromatography electrospray ionization tandem mass spectrometry and its application to pharmacokinetic study. Talanta 2007; 72: 1500–1506
   PubMed Web of Science ®Google Scholar
• Zhang Y., Benet L. Z. The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet. 2001; 40: 159–168
   PubMed Web of Science ®Google Scholar